Twist Bioscience Corp SEC 10-Q Report

Twist Bioscience Corp, a leading company in the synthetic biology and genomics industry, has released its Form 10-Q report for the second quarter of 2025. The report highlights significant financial and operational achievements, reflecting the company's growth and strategic initiatives in the synthetic biology market.

Financial Highlights

• Total Revenue: $96.1 million, an 18% increase from $81.5 million, driven by growth in NGS tools and synthetic genes revenues.
• Gross Profit: $51.3 million, a 45% increase from $35.3 million, with gross margin improving to 53.4% from 43.3% due to increased revenues and stable manufacturing costs.
• Loss from Operations: $(30.1) million, a significant decrease from $(88.9) million, primarily due to the absence of impairment charges and increased revenues.
• Net Income: $20.4 million, compared to a net loss of $(85.6) million in the prior year, driven by a gain on the sale of the DNA digital data storage business.
• Net Income Per Share, Basic: $0.34, compared to a loss per share of $(1.47) in the prior year.
• Net Income Per Share, Diluted: $0.33, compared to a loss per share of $(1.47) in the prior year.

Business Highlights

• Revenue Segments: The company reported an 18% increase in revenues for the three months ended June 30, 2025, driven primarily by growth in NGS tools and synthetic genes. NGS tools accounted for 57% of total revenues, while synthetic genes contributed 29%.
• Geographical Performance: The Americas region remains the largest market, contributing 62% of total revenues, followed by EMEA at 32%, and APAC at 6%. The EMEA region saw a notable increase in revenue share from 30% to 32% year-over-year.
• Sales Units: The number of genes shipped increased by 12% to approximately 237,000 for the three months ended June 30, 2025, compared to 212,000 in the same period in 2024. This reflects a growing demand for the company's synthetic gene products.
• Operational Efficiency: The company achieved a gross margin increase to 53.4% from 43.3% in the prior year, attributed to increased revenues and stable manufacturing costs, alongside continuous process improvements.
• Research and Development: R&D expenses decreased by 20% due to reduced personnel costs and stock-based compensation, following the transition of employees related to the sale of the DNA digital data storage business.
• Selling, General and Administrative Expenses: These expenses increased by 12%, driven by higher stock-based compensation, personnel costs, and marketing expenses, reflecting the company's investment in expanding its market presence.
• Future Outlook: The company expects to leverage its investment in the Wilsonville, Oregon manufacturing facility to support future growth and profitability, focusing on expanding its synthetic biology and biologic drug product lines.

SEC Filing: Twist Bioscience Corp [ TWST ] - 10-Q - Aug. 04, 2025